Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
63.81
-3.95 (-5.83%)
At close: Oct 22, 2026, 4:00 PM EDT
63.10
-0.71 (-1.11%)
After-hours: Oct 22, 2026, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $382.49M in the quarter ending June 30, 2026, with 21.56% growth. This brings the company's total for the last twelve months to $1.43B, up 50.43% year-over-year. In the year 2025, Tempus AI had annual revenue of $1.27B with 83.41% growth. That makes Tempus AI the 6,120th largest company in the world by revenue and 1,533rd in the United States.
Revenue (ttm)
$1.43B
Revenue Growth
+50.43%
P/S Ratio
8.04
Revenue / Employee
$376,847
Employees
3,800
Market Cap
11.51B
Revenue by Segment
- Genomics 955.38M 75.1%
- Data and Services 316.41M 24.9%
Fiscal year ended Dec 31, 2025 See the full Tempus AI breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 578.39M | 83.41% |
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 14.37B |
| Veeva Systems | 3.46B |
| Privia Health Group | 2.36B |
| HealthEquity | 1.36B |
| Omnicell | 1.25B |
| Waystar Holding | 1.21B |
| Hinge Health | 720.06M |
| Doximity | 655.57M |
TEM News
- 13 hours ago - How Tempus AI Built a Defensible Data Moat in Precision Healthcare - ETF Trends
- 3 days ago - Tempus AI presents data on pre-screening panel for NSCLC - TheFly
- 3 days ago - Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC - Business Wire
- 7 days ago - Tempus to Report Third Quarter 2026 Financial Results on November 2 - Business Wire
- 8 days ago - Tempus AI price target raised to $70 from $45 at JPMorgan - TheFly
- 9 days ago - Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases - Business Wire
- 10 days ago - Tempus AI price target raised to $95 from $80 at Canaccord - TheFly
- 13 days ago - Tempus AI price target raised to $75 from $52 at BofA - TheFly